Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry
27.08.2025 15:31
Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division’s (NAD) inquiry.New York, NY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ Nat
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
27.08.2025 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?
25.08.2025 06:57
Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.
Hartford Healthcare Fund Q2 2025 Commentary
21.08.2025 10:25
The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.
Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged
19.08.2025 03:15
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624. The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the […]
Vortex Energy Successfully Deploys ANT Sensors at Robinsons River Salt Project
14.08.2025 12:00
Vortex Energy Advancing Subsurface Imaging at the Robinsons River Salt ProjectVANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that all Ambient Noise Tomography (“ANT”) sensors have been successfully deployed across the Robinsons River Salt Project, located in Newfoundland and Labrador. This milestone follows the August 5, 2025 announcement of crew mobilization for the survey.
The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
13.08.2025 04:01
Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply negatively. Management pointed to strong commercial execution in its cystic fibrosis franchise, growing uptake of new therapies like ALYFTREK and JOURNAVX, and expanding momentum for CASGEVY in sickle cell disease and beta thalassemia. CEO Reshma Kewalramani highlighted that “momentum accelerated, and we executed with very strong performance across the board, growing and dive
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market
13.08.2025 03:53
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.
Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point
12.08.2025 10:50
NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community and...
The Best Stocks to Invest $1,000 In Right Now
07.08.2025 08:40
Market volatility could increase in the months ahead, but these stocks should hold up well.
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million
07.08.2025 05:31
Vertex Pharmaceuticals (VRTX) recently announced strong financial results with Q2 2025 revenue increasing to $2,965 million from $2,646 million in Q2 2024, and net income turning positive. Despite this, the share price fell 10.23% over the last quarter. The positive earnings were in juxtaposition to the halted development of VX-993 following disappointing study results and the impact of being removed from Russell indexes. Meanwhile, broader market gains were influenced by rising stocks in...
Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project
05.08.2025 12:00
Field Crews Begin Deployment of Ant Sensors to Image Subsurface at Robinsons RiverVANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to initiate the deployment of Ambient Noise Tomography (“ANT”) sensors. This marks the start of the Company’s flagship geophysical survey designed to image the subs
Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors.
05.08.2025 10:18
Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.
US stock futures higher amid mixed corporate earnings
05.08.2025 10:13
Palantir reported better-than-expected quarterly results, but restaurant chain Denny's and Hims & Hers Health posted disappointing results.
Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
05.08.2025 07:03
Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges in market access and R&D investments.
Vertex plan to build on pain drug breakthrough hits hurdles
05.08.2025 06:31
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
01.08.2025 16:04
Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out why FOLD stock is a Buy.
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
01.08.2025 10:30
These growth stocks have plenty of room to run.
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
29.07.2025 14:00
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
29.07.2025 13:14
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.